Cohance Lifesciences Ltd

Cohance Lifesciences Ltd

Cohance Lifesciences advances its ADC strategy by investing USD 18 million in NJ Bio and Aruka Bio, strengthening its commercial alignment and giving dedicated leadership focus to Aruka's novel drug development pipeline.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy, investing USD 13 million in NJ Bio and USD 5 million in Aruka Bio, increasing its stake in NJ Bio from 56% to 67.3% and acquiring a controlling stake in Aruka Bio.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced an investors meet on 1 September 2026 at Ashwamedh - Elara India Dialogue 2026 in Mumbai, where the company's management will be present for group and one-on-one interactions. The schedule is subject to change and no unpublished price-sensitive information will be shared.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has published a newspaper advertisement regarding its 8th Annual General Meeting (AGM) and e-voting information.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has released its Annual Report 2026, detailing its financial performance and business progress for the FY 2025-26. The report highlights the company's focus on advancing the science of progress, with investments in capabilities that will shape its future. The report also includes key performance indicators, contribution to sustainable development goals, and materiality assessment.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced the notice of its 8th Annual General Meeting (AGM) to be held on September 17, 2026, through video conference. The meeting will consider and adopt the audited consolidated and standalone financial statements for the year ended March 31, 2026, along with the reports of the Board of Directors and the Auditors. The company has also announced the reappointment of Ms. Shweta Jalan as a Director, liable to retire by rotation.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced that CRISIL Ratings Limited has withdrawn its credit ratings assigned to certain lower-limit facilities of the company due to non-cooperation from the issuer. The company continues to maintain credit ratings from India Ratings and Research Private Limited.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from DSP Trustee Pvt Ltd.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd announced its Q1 FY27 earnings conference call transcript, highlighting a low quarter but expecting improvement in Q2FY27 with scheduled commercial program deliveries and restocking orders. The company is strengthening its safety and quality systems and progressing in its nucleic acid business and specialty chemicals, including agrochemicals.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has published a newspaper advertisement regarding its un-audited financial results for the quarter ended 30 June 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results are also available on the company's website.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has uploaded the audio recording of its conference call for the quarter ended 30 June 2026 on its website.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has completed a USFDA inspection of its manufacturing facility in Hyderabad, receiving five observations, none related to data integrity issues. The company is preparing a response and corrective actions.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, along with the details of the reorganization at Sapala Organics Private Limited, a subsidiary of the company. The board meeting was held on 5 August 2026, and the results were approved. The company has also announced the convening of the 8th Annual General Meeting (AGM) of the members on 17 September 2026.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, along with the reorganization of its subsidiary Sapala Organics Private Limited and the convening of its 8th Annual General Meeting on 17 September 2026.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has informed that the Nomination and Remuneration Committee has approved the grant of up to 1,97,48,317 stock options to eligible employees under the ESOP 2026, and the allotment of 30,190 equity shares to options grantees who have exercised options under the ESOP 2023. The details are annexed as Annexure 1 and Annexure 2.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has announced a conference call for investors and analysts to discuss the unaudited financial results for Q1 FY27, which will be declared on August 5, 2026.

Cohance Lifesciences Ltd

Cohance Lifesciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 05/08/2026 to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter ended 30 June 2026.